Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients

Area of Science:

• Pharmacology
• Clinical Pharmacology
• Drug Interactions

Background:

• Ponalrestat is a highly protein-bound aldose reductase inhibitor.
• Aldose reductase inhibitors are explored for managing diabetic complications.
• Warfarin is a common anticoagulant requiring careful monitoring for interactions.

Purpose of the Study:

• To evaluate potential drug interactions between ponalrestat and warfarin in diabetic patients.
• To assess the effect of ponalrestat on warfarin's protein binding and plasma concentrations.

Main Methods:

• An open-label trial involving twelve diabetic patients on stable warfarin therapy.
• Patients received ponalrestat (600 mg daily) for two weeks, with placebo periods before and after.
• Plasma warfarin levels, protein binding, and INR were monitored throughout the study.

Main Results:

• Ponalrestat did not cause significant changes in INR, total or unbound warfarin concentrations, or warfarin protein binding.
• In vitro studies showed displacement of warfarin only at high ponalrestat concentrations (500 µg/ml).
• Maximum observed ponalrestat concentrations in patients were around 100 µg/ml, below the in vitro interaction threshold.

Conclusions:

• No significant pharmacokinetic or pharmacodynamic interaction between ponalrestat and warfarin was observed in diabetic patients at the studied doses.
• The maximum plasma concentrations of ponalrestat achieved in patients were insufficient to cause clinically relevant displacement of warfarin from protein binding.